febuxostat has been researched along with sulfinpyrazone in 1 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (sulfinpyrazone) | Trials (sulfinpyrazone) | Recent Studies (post-2010) (sulfinpyrazone) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 1,122 | 172 | 32 |
| Protein | Taxonomy | febuxostat (IC50) | sulfinpyrazone (IC50) |
|---|---|---|---|
| fMet-Leu-Phe receptor | Homo sapiens (human) | 14.4 | |
| fMet-Leu-Phe receptor | Homo sapiens (human) | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aviña-Zubieta, JA; Choi, HK; De Vera, MA; McCormick, N; Rai, SK; Sayre, EC; Shojania, K | 1 |
1 other study(ies) available for febuxostat and sulfinpyrazone
| Article | Year |
|---|---|
The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012.
Topics: Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; British Columbia; Colchicine; Comorbidity; Diabetes Mellitus; Febuxostat; Female; Glucocorticoids; Gout; Gout Suppressants; Humans; Hyperlipidemias; Hypertension; Incidence; Male; Middle Aged; Population Growth; Prevalence; Probenecid; Sulfinpyrazone; Uricosuric Agents | 2017 |